ArticleFrontiers in bioengineering and biotechnology2026
Comparative biodegradation of functionalized graphene oxide nanosheets by myeloperoxidase and neutrophil extracellular traps.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Graphene oxide (GO) nanosheets have attracted significant interest as potential carriers for drug delivery due to their unique physicochemical properties and large surface area. However, concerns regarding their cytotoxicity and biodegradability must be addressed before clinical translation. In this study, we aimed to evaluate the biocompatibility and biodegradation of GO functionalized with polyethylene glycol (PEG) and polyethyleneimine (PEI), two commonly used polymers in biomedical applications. Method: The interactions of GO, GO-PEG, and GO-PEI with granulocyte-like cells were investigated to determine their effects on cell viability and their susceptibility to immune-mediated degradation. Biodegradation of the materials was assessed using Raman spectroscopy after exposure to granulocyte-like cells, neutrophil extracellular traps (NETs), and myeloperoxidase (MPO), a key enzyme present in NETs. In addition, circular dichroism (CD) spectroscopy was used to evaluate structural changes in MPO upon interaction with the materials, and molecular dynamics simulations were performed to investigate the interaction of hypochlorous acid (HOCl), the catalytic product of MPO, with GO and its functionalized derivatives. Results and discussion: The results showed that functionalization with PEG or PEI significantly improved cell viability compared with pristine GO. Although GO was structurally modified by granulocyte-like cells, NETs, and MPO, GO-PEG did not show significant degradation under these conditions. In contrast, GO-PEI was susceptible to structural modification by both NETs and MPO. CD analysis indicated that MPO maintained a more stable secondary structure in the presence of GO-PEI compared with GO or GO-PEG under oxidative conditions, suggesting that MPO-generated HOCl may play a key role in GO-PEI degradation. Molecular dynamics simulations further demonstrated stronger interaction and retention of HOCl in GO-PEG and GO-PEI systems compared with pristine GO, indicating an enhanced interaction between oxidants and the functionalized materials. Overall, these findings demonstrate that polymer functionalization significantly influences the biocompatibility and immune-mediated structural modification of GO. Importantly, this study provides new mechanistic insights into how PEG and PEI modifications affect MPO-driven oxidative degradation pathways of graphene oxide-based nanomaterials. These results highlight GO-PEI as a biodegradable and biocompatible candidate for future biomedical and drug delivery applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.